ArticleBMC microbiology2026
Molecular profiling and computational mutational analysis of bla-NDM-1 in clinical Acinetobacter baumannii isolates.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAcinetobacter baumannii is the major cause of healthcare-associated infections attributed to its remarkable ability to resist multiple antibiotics. The study aimed to characterize the clinical A. baumannii isolates, evaluate their antibiotic resistance patterns, determine the prevalence of bla-NDM-1 gene, and perform in-silico mutational analysis to evaluate the structural and functional impact of its variant.
methodsIsolates were cultured on blood and MacConkey agars, identified at biochemical (API 20NE) and molecular levels, and assessed their antibiotic susceptibility using the Kirby-Bauer and MIC assays. PCR and sequencing analyses were performed to detect the variant of bla-NDM. A model of the wild-type bla-NDM-1 structure was created by AlphaFold, while the mutant P28A was generated and refined in PyMOL and validated by SAVES, GOR IV, and stability prediction tools.
resultsResistance among isolates was seen to multiple antibiotics used in this study, such as carbapenem, aminoglycoside, fluoroquinolone, and penicillin, while sensitivity was retained to colistin, polymyxin B, and tigecycline. Based on the antibiotic resistance profiles, 25.3% and 69.3% of the isolates were categorized as multi-drug resistant (MDR) and extensively drug-resistant (XDR), respectively, with 82.7% of isolates showing MAR index > 0.2. Mutation in a bla-NDM gene was observed only in 8% (n = 6) of the isolates belonging to A. baumannii and found to possess C→G substitution (P28A). In-silico study showed slight differences in the structure, decreased stability, and greater flexibility, indicating that the mutation is likely neutral and adaptive.
conclusionsThe threat posed by MDR A. baumannii strains is significant; hence, their detection, infection control, and genetic screening are critical for preventing further transmission, limiting severe complications, and minimizing patient mortality rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.